Latest Breaking News On - Catalyst biosciences inc - Page 1 : comparemela.com

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Data readout from Phase 3 clinical trial in the People s Republic of China evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial.

United statesJapan generalSan diegoChan yingStephen jasperRodneyl nussbaumPreclinical development updatesNational reimbursement drug listAudit committeeClinical development updatesExchange commissionCatalyst biosciences incCompany board of directorsArthur andersenContinent pharmaceuticals co ltdGyre therapeutics inc

Gyre Therapeutics, Inc : Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Gyre Therapeutics, Inc : Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJapan generalChan yingSan diegoDennis riedlStephen jasperRodneyl nussbaumCatalyst biosciences incGyre therapeutics incGc biopharma corpPreclinical development updatesCompany board of directorsGyre pharmaceuticalsErnst youngAudit committeeNational reimbursement drug list

Catalyst Biosciences : GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts - Form 8-K -December 06, 2023 at 04:05 pm EST

GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts GNI Group Ltd., today announced.

United statesGroup updates other incomeGyre therapeutics incGroup ltdCatalyst biosciences incFull yearEarnings forecastsGyre therapeuticsCatalyst biosciencesGyre seriesx convertible preferred stockGyre certificateSeriesx convertible preferred stockNasdaq capital market

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

SAN DIEGO, Nov. 13, 2023 Gyre Therapeutics , a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic liver diseases, today announced the.

United statesSan diegoStephen jasperCharles wuXianjun xuDepartment of gastroenterologyCatalyst biosciences incContinent pharmaceuticals ltdMedicines product administration of chinaShanghai jiao tong university school of medicineAmerican associationLiver diseasePannual liver meetingMetabolic dysfunction associated steatohepatitisChief executive officerTumor growth transforming

Bionomics : Notice of Annual General Meeting Explanatory Statement and Proxy Form - Form 6-K -November 03, 2023 at 06:10 am EDT

Notice of Annual General Meeting Explanatory Statement and Proxy Form Date of Meeting: Thursday, 30 November 2023 Time of Meeting: .

City ofUnited kingdomSouth australiaUnited statesJane ryanDupont merckRajeev chandraBiodel incSynaptic pharmaceutical corpAllen overyNational institutes of healthCredit suisse groupMeeting of shareholders bionomics limited companyNeuropore therapies incComputershare investor services ptyMeeting of the company